Nokia Oyj
Changes in Nokia Corporation's own shares
Changes in Nokia Corporation's own shares
Nokia Corporation
Stock Exchange Release
8 April 2025 at 14:30 EET
Changes in Nokia Corporation's own shares
Espoo, Finland – A total of 3 935 723 Nokia shares (NOKIA) held by the company were transferred today without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 22 November 2024.
The number of own shares held by Nokia Corporation following the transfer is 216 573 408.
About Nokia
At Nokia, we create technology that helps the world act together.
As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs, which is celebrating 100 years of innovation.
With truly open architectures that seamlessly integrate into any ecosystem, our high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with us to create the digital services and applications of the future.
Inquiries:
Nokia Communications
Phone: +358 10 448 4900
Email: press.services@nokia.com
Maria Vaismaa, Global Head of External Communications
Nokia
Investor Relations
Phone: +358 931 580 507
Email: investor.relations@nokia.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN17.4.2025 01:25:40 CEST | Press release
CGTN: China, Malaysia join forces for high-level strategic community with shared future
Biosidus16.4.2025 22:44:06 CEST | Press release
Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease
WillScot16.4.2025 22:05:00 CEST | Press release
WillScot to Announce First Quarter 2025 Results on May 1, 2025
Bavarian Nordic A/S16.4.2025 22:04:08 CEST | Press release
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
Bavarian Nordic A/S16.4.2025 22:04:08 CEST | Pressemeddelelse
Bavarian Nordics chikungunyavaccine modtager anbefaling af de amerikanske sundhedsmyndigheders rådgivningskomité (ACIP)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom